

1 Section 2-204. The controlled substances listed in this section
2 are included in Schedule I and include any material, compound,
3 mixture or preparation that contains any quantity of the following
4 hallucinogenic substances, their salts, isomers and salts of
5 isomers, unless specifically excepted, when the existence of these
6 salts, isomers and salts of isomers is possible within the specific
7 chemical designation.

8 A. Any of the following opiates including their isomers,
9 esters, ethers, salts, and salts of isomers, esters, and ethers,
10 unless specifically excepted, when the existence of these isomers,
11 esters, ethers, and salts is possible within the specific chemical
12 designation:

- 13 1. Acetylmethadol;
- 14 2. Allylprodine;
- 15 3. Alphacetylmethadol;
- 16 4. Alphameprodine;
- 17 5. Alphamethadol;
- 18 6. Benzethidine;
- 19 7. Betacetylmethadol;
- 20 8. Betameprodine;
- 21 9. Betamethadol;
- 22 10. Betaprodine;
- 23 11. Clonitazene;
- 24 12. Dextromoramide;

- 1 13. Dextrorphan (except its methyl ether);
- 2 14. Diampromide;
- 3 15. Diethylthiambutene;
- 4 16. Dimenoxadol;
- 5 17. Dimepheptanol;
- 6 18. Dimethylthiambutene;
- 7 19. Dioxaphetyl butyrate;
- 8 20. Dipipanone;
- 9 21. Ethylmethylthiambutene;
- 10 22. Etonitazene;
- 11 23. Etoxeridine;
- 12 24. Furethidine;
- 13 25. Hydroxypethidine;
- 14 26. Isotonitazene;
- 15 27. Ketobemidone;
- 16 28. Levomoramide;
- 17 29. Levophenacymorphan;
- 18 30. Metonitazene;
- 19 31. Morpheridine;
- 20 32. N-desethyl isotonitazene;
- 21 33. N-pyrrolidino protonitazene;
- 22 34. Noracymethadol;
- 23 35. Norlevorphanol;
- 24 36. Normethadone;

- 1 37. Norpipanone;
- 2 38. Phenadoxone;
- 3 39. Phenampromide;
- 4 40. Phenomorphan;
- 5 41. Phenoperidine;
- 6 42. Piritramide;
- 7 43. Proheptazine;
- 8 44. Properidine;
- 9 45. Protonitazene;
- 10 46. Racemoramide; or
- 11 47. Trimeperidine.

12 B. Any of the following opium derivatives, their salts,
13 isomers, and salts of isomers, unless specifically excepted, when
14 the existence of these salts, isomers, and salts of isomers is
15 possible within the specific chemical designation:

- 16 1. Acetorphine;
- 17 2. Acetyldihydrocodeine;
- 18 3. Benzylmorphine;
- 19 4. Codeine methylbromide;
- 20 5. Codeine-N-Oxide;
- 21 6. Cyprenorphine;
- 22 7. Desomorphine;
- 23 8. Dihydromorphine;
- 24 9. Etorphine;

- 1 10. Heroin;
- 2 11. Hydromorphenol;
- 3 12. Methyldesorphine;
- 4 13. Methylhydromorphine;
- 5 14. Morphine methylbromide;
- 6 15. Morphine methylsulfonate;
- 7 16. Morphine-N-Oxide;
- 8 17. Myrophine;
- 9 18. Nicocodeine;
- 10 19. Nicomorphine;
- 11 20. Normorphine;
- 12 21. Phoclodine;
- 13 22. Thebacon;
- 14 23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide
15 (Acetyl fentanyl);
- 16 24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide
17 (Crotonyl fentanyl);
- 18 25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
19 furancarboxamide (Furanyl fentanyl);
- 20 26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
- 21 27. N-(1-phenethylpiperidin-4-yl)-N-
22 phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or
- 23 28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide
24 (Butyryl fentanyl).

1 C. Any material, compound, mixture, or preparation which
2 contains any quantity of the following hallucinogenic substances,
3 their salts, isomers, and salts of isomers, unless specifically
4 excepted, when the existence of these salts, isomers, and salts of
5 isomers is possible within the specific chemical designation:

- 6 1. Methcathinone;
- 7 2. 3, 4-methylenedioxy amphetamine;
- 8 3. 3, 4-methylenedioxy methamphetamine;
- 9 4. 5-methoxy-3, 4-methylenedioxy amphetamine;
- 10 5. 3, 4, 5-trimethoxy amphetamine;
- 11 6. Bufotenine;
- 12 7. Diethyltryptamine;
- 13 8. Dimethyltryptamine;
- 14 9. 4-methyl-2, 5-dimethoxyamphetamine;
- 15 10. Ibogaine;
- 16 11. Lysergic acid diethylamide;
- 17 12. Marijuana;
- 18 13. Mescaline;
- 19 14. N-benzylpiperazine;
- 20 15. N-ethyl-3-piperidyl benzilate;
- 21 16. N-methyl-3-piperidyl benzilate;
- 22 17. Psilocybin;
- 23 18. Psilocyn;
- 24 19. 2, 5 dimethoxyamphetamine;

- 1 20. 4-Bromo-2,5-dimethoxyamphetamine;
- 2 21. 4-methoxyamphetamine;
- 3 22. Cyclohexamine;
- 4 23. Salvia Divinorum;
- 5 24. Salvinorin A;
- 6 25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-
- 7 thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of Phencyclidine;
- 8 TPCP, TCP;
- 9 26. Phencyclidine (PCP);
- 10 27. Pyrrolidine Analog for Phencyclidine. Also known as 1-(1-
- 11 Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;
- 12 28. 1-(3-trifluoromethylphenyl) piperazine;
- 13 29. Flunitrazepam;
- 14 30. B-hydroxy-amphetamine;
- 15 31. B-ketoamphetamine;
- 16 32. 2,5-dimethoxy-4-nitroamphetamine;
- 17 33. 2,5-dimethoxy-4-bromophenethylamine;
- 18 34. 2,5-dimethoxy-4-chlorophenethylamine;
- 19 35. 2,5-dimethoxy-4-iodoamphetamine;
- 20 36. 2,5-dimethoxy-4-iodophenethylamine;
- 21 37. 2,5-dimethoxy-4-methylphenethylamine;
- 22 38. 2,5-dimethoxy-4-ethylphenethylamine;
- 23 39. 2,5-dimethoxy-4-fluorophenethylamine;
- 24 40. 2,5-dimethoxy-4-nitrophenethylamine;

- 1 41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
- 2 42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
- 3 43. 2,5-dimethoxy-4-propylthio-phenethylamine;
- 4 44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine;
- 5 45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
- 6 46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
- 7 47. 5-methoxy-N, N-dimethyltryptamine;
- 8 48. N-methyltryptamine;
- 9 49. A-ethyltryptamine;
- 10 50. A-methyltryptamine;
- 11 51. N, N-diethyltryptamine;
- 12 52. N, N-diisopropyltryptamine;
- 13 53. N, N-dipropyltryptamine;
- 14 54. 5-methoxy-a-methyltryptamine;
- 15 55. 4-hydroxy-N, N-diethyltryptamine;
- 16 56. 4-hydroxy-N, N-diisopropyltryptamine;
- 17 57. 5-methoxy-N, N-diisopropyltryptamine;
- 18 58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
- 19 59. 3,4-Methylenedioxy-methcathinone (Mephedrone);
- 20 60. 3,4-Methylenedioxy-pyrovalerone (MDPV);
- 21 61. 3-Methylmethcathinone (Metaphedrone);
- 22 62. 4-Methylmethcathinone (Mephedrone);
- 23 63. 4-methoxymethcathinone;
- 24 64. 4-Fluoromethcathinone;

- 1 65. 3-Fluoromethcathinone;
- 2 66. 1-(8-bromobenzo 1,2-b;4,5-b' difuran-4-yl)-2-aminopropane;
- 3 67. 2,5-Dimethoxy-4-chloroamphetamine;
- 4 68. 4-Methylethcathinone;
- 5 69. Pyrovalerone;
- 6 70. N,N-diallyl-5-methoxytryptamine;
- 7 71. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
- 8 72. B-keto-N-Methylbenzodioxolylbutanamine (Butylone);
- 9 73. B-keto-Methylbenzodioxolylpentanamine (Pentylone);
- 10 74. Alpha-Pyrrolidinopentiophenone;
- 11 75. 4-Fluoroamphetamine;
- 12 76. Pentedrone;
- 13 77. 4'-Methyl-a-pyrrolidinohexaphenone;
- 14 78. 2,5-dimethoxy-4-(n)-propylphenethylamine;
- 15 79. 2,5-dimethoxyphenethylamine;
- 16 80. 1,4-Dibenzylpiperazine;
- 17 81. N,N-Dimethylamphetamine;
- 18 82. 4-Fluoromethamphetamine;
- 19 83. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
20 (25C-NBOMe);
- 21 84. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
22 (25I-NBOMe);
- 23 85. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine
24 (25B-NBOMe);

- 1 86. 1-(4-Fluorophenyl)piperazine;
- 2 87. Methoxetamine;
- 3 88. 3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N-
- 4 methylbenzamide;
- 5 89. N-ethyl hexadrone;
- 6 90. Isopropyl-U-47700;
- 7 91. Para-fluorobutyrl fentanyl;
- 8 92. Para-fluorofentanyl (pFF);
- 9 93. Fluoro isobutryrl fentanyl;
- 10 94. 3-Hydroxy Phencyclidine (PCP);
- 11 95. 3-methoxy Phencyclidine (PCP);
- 12 96. Flualprazolam; or
- 13 97. Flubromazolam.

14 D. Unless specifically excepted or unless listed in a different
15 schedule, any material, compound, mixture, or preparation which
16 contains any quantity of the following substances having stimulant
17 or depressant effect on the central nervous system:

- 18 1. Fenethylline;
- 19 2. Mecloqualone;
- 20 3. N-ethylamphetamine;
- 21 4. Methaqualone;
- 22 5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma-
- 23 hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium
- 24 oxybate, and sodium oxybutyrate;

1 6. Gamma-Butyrolactone (GBL) as packaged, marketed,
2 manufactured or promoted for human consumption, with the exception
3 of legitimate food additive and manufacturing purposes;

4 7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or
5 manufactured for human consumption, with the exception of legitimate
6 food additive and manufacturing purposes;

7 8. Gamma Valerolactone (GVL) as packaged, marketed, or
8 manufactured for human consumption, with the exception of legitimate
9 food additive and manufacturing purposes;

10 9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed,
11 manufactured, or promoted for human consumption with the exception
12 of legitimate manufacturing purposes; ~~or~~

13 10. N-ethylpentylone;

14 11. Adinazolam;

15 12. Meclonazepam;

16 13. N-methylclonazepam;

17 14. Bromazolam;

18 15. Flunitrazolam;

19 16. Nitrazolam;

20 17. Pyrazolam; or

21 18. Zapizolam.

22 E. 1. The following industrial uses of Gamma-Butyrolactone,
23 Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are
24

1 excluded from all schedules of controlled substances under this
2 title:

- 3 a. pesticides,
- 4 b. photochemical etching,
- 5 c. electrolytes of small batteries or capacitors,
- 6 d. viscosity modifiers in polyurethane,
- 7 e. surface etching of metal coated plastics,
- 8 f. organic paint disbursements for water soluble inks,
- 9 g. pH regulators in the dyeing of wool and polyamide
10 fibers,
- 11 h. foundry chemistry as a catalyst during curing,
- 12 i. curing agents in many coating systems based on
13 urethanes and amides,
- 14 j. additives and flavoring agents in food, confectionary,
15 and beverage products,
- 16 k. synthetic fiber and clothing production,
- 17 l. tetrahydrofuran production,
- 18 m. gamma butyrolactone production,
- 19 n. polybutylene terephthalate resin production,
- 20 o. polyester raw materials for polyurethane elastomers
21 and foams,
- 22 p. coating resin raw material, and
23 q. as an intermediate in the manufacture of other
24 chemicals and pharmaceuticals.

1 2. At the request of any person, the Director of the Oklahoma
2 State Bureau of Narcotics and Dangerous Drugs Control may exempt any
3 other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate,
4 Gamma Valerolactone, or 1,4 Butanediol from being included as a
5 Schedule I controlled substance if such product is labeled,
6 marketed, manufactured and distributed for legitimate industrial use
7 in a manner that reduces or eliminates the likelihood of abuse.

8 3. In making a determination regarding an industrial product,
9 the Director, after notice and hearing, shall consider the
10 following:

- 11 a. the history and current pattern of abuse,
- 12 b. the name and labeling of the product,
- 13 c. the intended manner of distribution, advertising and
14 promotion of the product, and
- 15 d. other factors as may be relevant to and consistent
16 with the public health and safety.

17 4. The hearing shall be held in accordance with the procedures
18 of the Administrative Procedures Act.

19 F. Any material, compound, mixture, or preparation, whether
20 produced directly or indirectly from a substance of vegetable origin
21 or independently by means of chemical synthesis, or by a combination
22 of extraction and chemical synthesis, that contains any quantity of
23 the following substances, or that contains any of their salts,
24 isomers, and salts of isomers when the existence of these salts,

1 isomers, and salts of isomers is possible within the specific
2 chemical designation:

- 3 1. JWH-004;
- 4 2. JWH-007;
- 5 3. JWH-009;
- 6 4. JWH-015;
- 7 5. JWH-016;
- 8 6. JWH-018;
- 9 7. JWH-019;
- 10 8. JWH-020;
- 11 9. JWH-030;
- 12 10. JWH-046;
- 13 11. JWH-047;
- 14 12. JWH-048;
- 15 13. JWH-049;
- 16 14. JWH-050;
- 17 15. JWH-070;
- 18 16. JWH-071;
- 19 17. JWH-072;
- 20 18. JWH-073;
- 21 19. JWH-076;
- 22 20. JWH-079;
- 23 21. JWH-080;
- 24 22. JWH-081;

- 1 23. JWH-082;
- 2 24. JWH-094;
- 3 25. JWH-096;
- 4 26. JWH-098;
- 5 27. JWH-116;
- 6 28. JWH-120;
- 7 29. JWH-122;
- 8 30. JWH-145;
- 9 31. JWH-146;
- 10 32. JWH-147;
- 11 33. JWH-148;
- 12 34. JWH-149;
- 13 35. JWH-150;
- 14 36. JWH-156;
- 15 37. JWH-167;
- 16 38. JWH-175;
- 17 39. JWH-180;
- 18 40. JWH-181;
- 19 41. JWH-182;
- 20 42. JWH-184;
- 21 43. JWH-185;
- 22 44. JWH-189;
- 23 45. JWH-192;
- 24 46. JWH-193;

- 1 47. JWH-194;
- 2 48. JWH-195;
- 3 49. JWH-196;
- 4 50. JWH-197;
- 5 51. JWH-198;
- 6 52. JWH-199;
- 7 53. JWH-200;
- 8 54. JWH-201;
- 9 55. JWH-202;
- 10 56. JWH-203;
- 11 57. JWH-204;
- 12 58. JWH-205;
- 13 59. JWH-206;
- 14 60. JWH-207;
- 15 61. JWH-208;
- 16 62. JWH-209;
- 17 63. JWH-210;
- 18 64. JWH-211;
- 19 65. JWH-212;
- 20 66. JWH-213;
- 21 67. JWH-234;
- 22 68. JWH-235;
- 23 69. JWH-236;
- 24 70. JWH-237;

- 1 71. JWH-239;
- 2 72. JWH-240;
- 3 73. JWH-241;
- 4 74. JWH-242;
- 5 75. JWH-243;
- 6 76. JWH-244;
- 7 77. JWH-245;
- 8 78. JWH-246;
- 9 79. JWH-248;
- 10 80. JWH-249;
- 11 81. JWH-250;
- 12 82. JWH-251;
- 13 83. JWH-252;
- 14 84. JWH-253;
- 15 85. JWH-262;
- 16 86. JWH-292;
- 17 87. JWH-293;
- 18 88. JWH-302;
- 19 89. JWH-303;
- 20 90. JWH-304;
- 21 91. JWH-305;
- 22 92. JWH-306;
- 23 93. JWH-307;
- 24 94. JWH-308;

- 1 95. JWH-311;
- 2 96. JWH-312;
- 3 97. JWH-313;
- 4 98. JWH-314;
- 5 99. JWH-315;
- 6 100. JWH-316;
- 7 101. JWH-346;
- 8 102. JWH-348;
- 9 103. JWH-363;
- 10 104. JWH-364;
- 11 105. JWH-365;
- 12 106. JWH-367;
- 13 107. JWH-368;
- 14 108. JWH-369;
- 15 109. JWH-370;
- 16 110. JWH-371;
- 17 111. JWH-373;
- 18 112. JWH-386;
- 19 113. JWH-387;
- 20 114. JWH-392;
- 21 115. JWH-394;
- 22 116. JWH-395;
- 23 117. JWH-397;
- 24 118. JWH-398;

- 1 119. JWH-399;
- 2 120. JWH-400;
- 3 121. JWH-412;
- 4 122. JWH-413;
- 5 123. JWH-414;
- 6 124. JWH-415;
- 7 125. CP-55, 940;
- 8 126. CP-47, 497;
- 9 127. HU-210;
- 10 128. HU-211;
- 11 129. WIN-55, 212-2;
- 12 130. AM-2201;
- 13 131. AM-2233;
- 14 132. JWH-018 adamantyl-carboxamide;
- 15 133. AKB48;
- 16 134. JWH-122 N-(4-pentenyl) analog;
- 17 135. MAM2201;
- 18 136. URB597;
- 19 137. URB602;
- 20 138. URB754;
- 21 139. UR144;
- 22 140. XLR11;
- 23 141. A-796,260;
- 24 142. STS-135;

- 1 143. AB-FUBINACA;
2 144. AB-PINACA;
3 145. PB-22;
4 146. AKB48 N-5-Fluoropentyl;
5 147. AM1248;
6 148. FUB-PB-22;
7 149. ADB-FUBINACA;
8 150. BB-22;
9 151. 5-Fluoro PB-22; or
10 152. 5-Fluoro AKB-48.

11 G. In addition to those substances listed in subsection F of
12 this section, unless specifically excepted or unless listed in
13 another schedule, any material, compound, mixture, or preparation
14 which contains any quantity of a synthetic cannabinoid found to be
15 in any of the following chemical groups:

16 1. Naphthoylindoles: any compound containing a 3-(1-
17 naphthoyl)indole structure with or without substitution at the
18 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
19 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
20 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
21 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
22 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
23 halophenyl group, whether or not further substituted on the indole
24 ring to any extent, and whether or not substituted on the naphthyl

1 ring to any extent. Naphthoylindoles include, but are not limited
2 to:

- 3 a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-
4 200),
- 5 b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
- 6 c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018),
- 7 d. 1-butyl-3-(1-naphthoyl)indole (JWH-073),
- 8 e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081),
- 9 f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015),
- 10 g. 1-hexyl-3-(1-naphthoyl)indole (JWH-019),
- 11 h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
- 12 i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210),
- 13 j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),
- 14 k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
- 15 l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164),
- 16 m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
17 (JWH-098),
- 18 n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412),
- 19 o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
20 naphthoyl)indole (AM-1220),
- 21 p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
22 (MAM-2201), or
- 23 q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232);

24

1 2. Naphthylmethyloindoles: any compound containing a 1H-indol-3-
2 yl-(1-naphthyl)methane structure with or without substitution at the
3 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
4 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
5 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
6 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
7 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
8 halophenyl group, whether or not further substituted on the indole
9 ring to any extent, and whether or not substituted on the naphthyl
10 ring to any extent. Naphthylmethyloindoles include, but are not
11 limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175);

12 3. Naphthoylpyrroles: any compound containing a 3-(1-
13 naphthoyl)pyrrole structure with or without substitution at the
14 nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
15 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
16 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
17 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
18 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
19 phenyl, or halophenyl group, whether or not further substituted on
20 the pyrrole ring to any extent, and whether or not substituted on
21 the naphthyl group to any extent. Naphthoylpyrroles include, but
22 are not limited to:

23 a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147),
24

1 b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole
2 (JWH-370),

3 c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or

4 d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH-147);

5 4. Naphthylideneindenes: any compound containing a 1-(1-
6 naphthylmethylene)indene structure with or without substitution at
7 the 3-position of the indene ring by an alkyl, haloalkyl,
8 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
9 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
10 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
11 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
12 phenyl, or halophenyl group, whether or not further substituted on
13 the indene group to any extent, and whether or not substituted on
14 the naphthyl group to any extent. Naphthylmethylindenes include,
15 but are not limited to, (1-[(3-pentyl)-1H-inden-1-
16 ylidene)methyl]naphthalene (JWH-176);

17 5. Phenylacetylindoles: any compound containing a 3-
18 phenylacetylindole structure with or without substitution at the
19 nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
20 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
21 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
22 2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
23 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
24 halophenyl group, whether or not further substituted on the indole

1 ring to any extent, and whether or not substituted on the phenyl
2 ring to any extent. Phenylacetylindoles include, but are not
3 limited to:

- 4 a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250),
- 5 b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
6 (RCS-8),
- 7 c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203),
- 8 d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251),
- 9 e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or
- 10 f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302);

11 6. Cyclohexylphenols: any compound containing a 2-(3-
12 hydroxycyclohexyl)phenol structure with or without substitution at
13 the 5-position of the phenolic ring by an alkyl, haloalkyl,
14 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
15 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
16 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
17 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
18 phenyl, or halophenyl group, and whether or not further substituted
19 on the cyclohexyl ring to any extent. Cyclohexylphenols include,
20 but are not limited to:

- 21 a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
22 hydroxycyclohexyl]-phenol (CP-47,497),

23
24

- 1 b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
2 phenol (cannabicyclohexanol; CP-47,497 C8 homologue),
3 or
4 c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
5 hydroxypropyl)cyclohexyl]-phenol (CP 55, 940);

6 7. Benzoylindoles: any compound containing a 3-(benzoyl)indole
7 structure with or without substitution at the nitrogen atom of the
8 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
9 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
10 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
11 pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
12 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
13 halophenyl group, whether or not further substituted on the indole
14 ring to any extent, and whether or not substituted on the phenyl
15 group to any extent. Benzoylindoles include, but are not limited
16 to:

- 17 a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4),
18 b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
19 methoxybenzoyl)indole (Pravadoline or WIN 48, 098),
20 c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694),
21 d. 1-pentyl-3-(2-iodobenzoyl)indole (AM-679), or
22 e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
23 iodobenzoyl)indole (AM-2233);
24

1 8. Cyclopropoylindoles: Any compound containing a 3-
2 (cyclopropoyl)indole structure with substitution at the nitrogen
3 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
5 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
6 pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
7 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
8 halophenyl group, whether or not further substituted in the indole
9 ring to any extent and whether or not substituted in the
10 cyclopropoyl ring to any extent. Cyclopropoylindoles include, but
11 are not limited to:

- 12 a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole
13 (UR-144),
- 14 b. 1-(5-chloropentyl)-3-(2,2,3,3-
15 tetramethylcyclopropoyl)indole (5Cl-UR-144), or
- 16 c. 1-(5-fluoropentyl)-3-(2,2,3,3-
17 tetramethylcyclopropoyl)indole (XLR11);

18 9. Indole Amides: Any compound containing a 1H-Indole-3-
19 carboxamide structure with or without substitution at the nitrogen
20 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
21 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
22 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
23 pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
24 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or

1 halophenyl group, whether or not substituted at the carboxamide
2 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
3 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
4 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
5 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
6 further substituted in the indole, adamantyl, naphthyl, phenyl,
7 pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole
8 Amides include, but are not limited to:

- 9 a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide
10 (2NE1),
- 11 b. N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indole-3-
12 carboxamide (STS-135),
- 13 c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
14 indole-3-carboxamide (ADBICA),
- 15 d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
16 fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
- 17 e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide
18 (NNE1),
- 19 f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
20 carboxamide (5F-NNE1),
- 21 g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
22 or
- 23 h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide
24 (5F-SDB-006);

1 10. Indole Esters: Any compound containing a 1H-Indole-3-
2 carboxylate structure with or without substitution at the nitrogen
3 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
4 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-
5 2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
6 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
7 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
8 halophenyl group, whether or not substituted at the carboxylate
9 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
10 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
11 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
12 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
13 further substituted in the indole, adamantyl, naphthyl, phenyl,
14 pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole
15 Esters include, but are not limited to:

- 16 a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
17 22),
- 18 b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
19 carboxylate (5F-PB-22),
- 20 c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
21 carboxylate (BB-22),
- 22 d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
23 carboxylate (FDU-PB-22), or

24

1 e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
2 carboxylate (NM2201);

3 11. Adamantanoylindoles: Any compound containing an
4 adamantanyl-(1H-indol-3-yl)methanone structure with or without
5 substitution at the nitrogen atom of the indole ring by an alkyl,
6 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
7 benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
8 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
9 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
10 phenyl, or halophenyl group, whether or not further substituted in
11 the indole ring to any extent and whether or not substituted in the
12 adamantyl ring to any extent. Adamantanoylindoles include, but are
13 not limited to:

14 a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
15 indol-3-yl]methanone (AM1248), or

16 b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
17 001);

18 12. Carbazole ~~Ketone~~ Ketones: Any compound containing (9H-
19 carbazole-3-yl) methanone structure with or without substitution at
20 the nitrogen atom of the carbazole ring by an alkyl, haloalkyl,
21 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
22 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
23 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
24 morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,

1 phenyl, or halophenyl group, with substitution at the carbon of the
2 methanone group by an adamantyl, naphthyl, phenyl, benzyl,
3 quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-
4 3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-
5 methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether
6 or not further substituted at the carbazole, adamantyl, naphthyl,
7 phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.
8 Carbazole Ketones include, but are not limited to, naphthalen-1-
9 yl(9-pentyl-9H-carbazol-3-yl)methanone (EG-018);

10 13. Benzimidazole ~~Ketone~~ Ketones: Any compound containing
11 (benzimidazole-2-yl) methanone structure with or without
12 substitution at either nitrogen atom of the benzimidazole ring by an
13 alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
14 cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-
15 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
16 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
17 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
18 halophenyl group, with substitution at the carbon of the methanone
19 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
20 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
21 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
22 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
23 further substituted in the benzimidazole, adamantyl, naphthyl,
24

1 phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.

2 Benzimidazole Ketones include, but are not limited to:

3 a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
4 l)methanone (JWH-018 benzimidazole analog), or

5 b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
6 yl)(naphthalen-1-yl)methanone (FUBIMINA); and

7 14. Modified by Replacement: any compound defined in this
8 subsection that is modified by replacement of a carbon with nitrogen
9 in the indole, naphthyl, indene, benzimidazole, or carbazole ring.

10 H. Any prescription drug approved by the federal Food and Drug
11 Administration under the provisions of Section 505 of the Federal
12 Food, Drug and Cosmetic Act, ~~Title 21 of the United States Code~~ (21
13 U.S.C., Section 355), that is designated, rescheduled or deleted as
14 a controlled substance under federal law by the United States Drug
15 Enforcement Administration shall be excluded from Schedule I and
16 shall be prescribed, distributed, dispensed or used in accordance
17 with federal law upon the issuance of a notice, final rule or
18 interim final rule by the United States Drug Enforcement
19 Administration designating, rescheduling or deleting as a controlled
20 substance such a drug product under federal law, unless and until
21 the State Board of Pharmacy takes action pursuant to Section 2-201
22 of this title. If the Board of Pharmacy does not take action
23 pursuant to Section 2-201 of this title, the drug product shall be
24 deemed to be designated, rescheduled or deleted as a controlled

1 substance in accordance with federal law and in compliance with the
2 Uniform Controlled Dangerous Substances Act.

3 SECTION 2. AMENDATORY 63 O.S. 2021, Section 2-210, is
4 amended to read as follows:

5 Section 2-210. A. Any material, compound, mixture, or
6 preparation which contains any quantity of the following substances
7 having a potential for abuse associated with a stimulant or
8 depressant effect on the central nervous system:

- 9 1. Chloral betaine;
- 10 2. Chloral hydrate;
- 11 3. Ethchlorvynol;
- 12 4. Ethinamate;
- 13 5. Meprobamate;
- 14 6. Paraldehyde;
- 15 7. Petrichloral;
- 16 8. Diethylpropion;
- 17 9. Phentermine;
- 18 10. Pemoline;
- 19 11. Chlordiazepoxide;
- 20 12. Chlordiazepoxide and its salts, but not including
21 chlordiazepoxide hydrochloride and clidinium bromide or
22 chlordiazepoxide and water-soluble esterified estrogens;
- 23 13. Diazepam;
- 24 14. Oxazepam;

- 1 15. Clorazepate;
- 2 16. Flurazepam and its salts;
- 3 17. Clonazepam;
- 4 18. Barbital;
- 5 19. Mebutamate;
- 6 20. Methohexital;
- 7 21. Methylphenobarbital;
- 8 22. Phenobarbital;
- 9 23. Fenfluramine;
- 10 24. Pentazocine;
- 11 25. Propoxyphene;
- 12 26. Butorphanol;
- 13 27. Alprazolam;
- 14 28. Halazepam;
- 15 29. Lorazepam;
- 16 30. Prazepam;
- 17 31. Temazepam;
- 18 32. Triazolam;
- 19 33. Carisoprodol;
- 20 34. Dichloralphenazone;
- 21 35. Estazolam;
- 22 36. Eszopiclone;
- 23 37. Midazolam;
- 24 38. Modafinil;

- 1 39. Zaleplon;
- 2 40. Zolpidem;
- 3 41. Tramadol;
- 4 42. Bromazepam;
- 5 43. Suvorexant;
- 6 44. Phenazepam;
- 7 45. Etizolam; ~~or~~
- 8 46. Clonazolam;
- 9 47. Lormetazepam; or
- 10 48. Nifoxipam.

11 B. 1. The following nonnarcotic substances, which may, under
12 the Federal Food, Drug, and Cosmetic Act (21 U.S.C., Section 301 et
13 seq.), be lawfully sold over the counter without a prescription, are
14 excluded from all schedules of controlled substances under this
15 title:

- 16 a. Breathe-Aid,
- 17 b. BronCare,
- 18 c. Bronchial Congestion,
- 19 d. Bronkaid Tablets,
- 20 e. Bronkaid Dual Action Caplets,
- 21 f. Bronkotabs,
- 22 g. Bronkolixir,
- 23 h. NeoRespin,
- 24 i. Pazo Hemorrhoid Ointment and Suppositories,

- 1 j. Primatene Tablets,
- 2 k. Primatene "Dual Action" Formula,
- 3 l. Quelidrine,
- 4 m. Resp, and
- 5 n. Vatronal Nose Drops.

6 2. At the request of any person, the Director of the Oklahoma
7 State Bureau of Narcotics and Dangerous Drugs Control may exempt any
8 other drug product containing ephedrine from being included as a
9 Schedule IV controlled substance if such product:

- 10 a. is labeled and marketed in a manner consistent with
11 the pertinent OTC tentative final or final monograph
12 issued by the Food and Drug Administration (FDA), and
- 13 b. is manufactured and distributed for legitimate
14 medicinal use and in a manner that reduces or
15 eliminates the likelihood of abuse.

16 3. In making a determination regarding a drug product, the
17 Director, after notice and hearing, shall consider the following:

- 18 a. the history and current pattern of abuse,
- 19 b. the name and labeling of the product,
- 20 c. the intended manner of distribution, advertising and
21 promotion of the product, and
- 22 d. other factors as may be relevant to and consistent
23 with the public health and safety.

1 4. The hearing shall be held in accordance with the
2 Administrative Procedures Act.

3 5. A list of current drug products meeting exemption
4 requirements under this subsection may be obtained from the Oklahoma
5 State Bureau of Narcotics and Dangerous Drugs Control upon written
6 request.

7 C. The State Board of Pharmacy may except by rule any compound,
8 mixture, or preparation containing any depressant substance listed
9 in subsection A of this section from the application of all or any
10 part of the Uniform Controlled Dangerous Substances Act, Section 2-
11 101 et seq. of this title, if the compound, mixture, or preparation
12 contains one or more active medicinal ingredients not having a
13 depressant effect on the central nervous system, and if the
14 admixtures are included therein in combinations, quantity,
15 proportion, or concentration that vitiate the potential for abuse of
16 the substances which have a depressant effect on the central nervous
17 system.

18 SECTION 3. AMENDATORY 63 O.S. 2021, Section 2-309B, as
19 amended by Section 1, Chapter 69, O.S.L. 2022 (63 O.S. Supp. 2025,
20 Section 2-309B), is amended to read as follows:

21 Section 2-309B. For the purposes of the Anti-Drug Diversion
22 Act:

23 1. "Bureau" means the Oklahoma State Bureau of Narcotics and
24 Dangerous Drugs Control;

1 2. "Dispenser" means a person who distributes a Schedule II,
2 III, IV, or V controlled dangerous substance, but does not include a
3 licensed hospital pharmacy or a licensed nurse or medication aide
4 who administers such a substance at the direction of a licensed
5 physician;

6 3. "Dispenser's registration number" means the dispenser's
7 Oklahoma State Bureau of Narcotics and Dangerous Drugs Control
8 registration number or, in the case of a pharmacist, the National
9 Association of Boards of Pharmacy number for the pharmacy where the
10 dispensation is made;

11 4. "Exception report" means an output of data indicating
12 Schedule II controlled dangerous substance dispensation which is
13 outside expected norms for a prescriber practicing a particular
14 specialty or field of health care, for a dispenser doing business in
15 a particular location, or for a recipient;

16 5. "Recipient" means the person for whom a prescription is
17 prescribed and who is the lawful intended ultimate user;

18 6. "Recipient's agent" means a person who is authorized by the
19 ultimate user to pick up the recipient's medication and deliver it
20 to the recipient or a person who claims a prescription other than
21 the person to whom the medication is prescribed;

22 7. "Recipient's identification number" and "recipient's agent's
23 identification number" ~~means~~ mean the unique number contained on
24 forms of identification either listed in 8 ~~CFR~~ C.F.R., Section

1 274a.2(b) (1) (v) (A) and (B) or as otherwise listed in the rules of
2 the Bureau;

3 8. "Registrant" means a person, persons, corporation or other
4 entity who has been issued by the Director of the Oklahoma State
5 Bureau of Narcotics and Dangerous Drugs Control a registration
6 pursuant to Section 2-302 of this title; and

7 9. "State" means any state, territory, or possession of the
8 United States, the District of Columbia, or foreign nation.

9 SECTION 4. This act shall become effective November 1, 2026.

10

11 COMMITTEE REPORT BY: COMMITTEE ON JUDICIARY AND PUBLIC SAFETY
12 OVERSIGHT, dated 02/26/2026 - DO PASS.

13

14

15

16

17

18

19

20

21

22

23

24